Gregg W. Stone, MD, FACC, MSCAI (he/him/his)

Physician
Mount Sinai
New York, New York, United States

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 140 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 3000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2021 H-factor of 194, Dr. Stone has been recognized in Nature Medicine as one of the most prolific authors in science, and by the Web of Science as among the top 0.01% of cited researchers in science.

Presentation(s):

• Challenges AND Opportunities FOR THE RECOVER IV Study

  Saturday, February 25, 2023
  11:38 AM – 11:46 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion | Is it Feasible to Conduct Meaningful Randomized Clinical Trials for Cardiogenic Shock in 2023 and Beyond

  Saturday, February 25, 2023
  11:54 AM – 12:10 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Revisiting Bivalirudin in STEMI: The BRIGHT IV Trial and Beyond

  Saturday, February 25, 2023
  3:39 PM – 3:47 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Is it Time to Treat Vulnerable Plaque? Insights from Pharmacology and Interventional Trials

  Saturday, February 25, 2023
  5:02 PM – 5:10 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion: Atherosclerosis Therapeutic Options and Management

  Saturday, February 25, 2023
  5:26 PM – 5:35 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Latest Update from COAPT

  Saturday, February 25, 2023
  4:31 PM – 4:39 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Lessons From FAVOR III Studies

  Saturday, February 25, 2023
  3:23 PM – 3:31 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion: Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy – Personalizing Treatment to Optimize Outcomes

  Saturday, February 25, 2023
  7:40 PM – 7:55 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• CARDIOTUBE INTERIVEW: Coronary Reducer and the Corsira study design

  Sunday, February 26, 2023
  10:15 AM – 10:25 AM ET

  Disclosure information not submitted.

• Late-Breaking Trials | Session Two

  Sunday, February 26, 2023
  8:00 AM – 9:00 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• LATE-BREAKING TRIALS | SESSION TWO

  Sunday, February 26, 2023
  8:00 AM – 9:00 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Hemodynamic Support for Elective PCI: Patient and Device Selection

  Sunday, February 26, 2023
  9:25 AM – 9:33 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion | Who Should get MCS for High-Risk PCI and with Which Device?

  Sunday, February 26, 2023
  9:41 AM – 10:00 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Late-Breaking Trials | Session Three

  Monday, February 27, 2023
  11:30 AM – 12:30 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• LATE-BREAKING TRIALS | SESSION THREE

  Monday, February 27, 2023
  11:30 AM – 12:30 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Complex Coronary Interventions | Monday Session (Non-CME)

  Monday, February 27, 2023
  2:00 PM – 5:33 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Live Case from Mount Sinai Hospital | New York, NY

  Monday, February 27, 2023
  2:00 PM – 2:45 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• My Forthcoming Device Trials That Would Impact Your Practice Late This Decade

  Monday, February 27, 2023
  2:53 PM – 3:01 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion | Forthcoming Pathways in Interventional Cardiology

  Monday, February 27, 2023
  3:30 PM – 3:45 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Live Case from Medstar Washington Hospital Center | Washington, DC

  Monday, February 27, 2023
  3:45 PM – 4:30 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• PCI 2023: CONTROVERSIES AND HOT TOPICS IN INTERVENTIONAL CARDIOLOGY

  Monday, February 27, 2023
  4:30 PM – 5:33 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• REDUCER for Refractory Angina: The COSIRA II Trial

  Monday, February 27, 2023
  5:09 PM – 5:21 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion | Challenges Designing Clinical Trials for Heart Failures Using the MCP Devices

  Tuesday, February 28, 2023
  8:59 AM – 9:30 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• LV Reshaping for Heart Failure: The Revivent Procedure and the ALIVE Trial

  Tuesday, February 28, 2023
  11:02 AM – 11:14 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• V-wave Interatrial Shunts for Heart Failure: The RELIEVE-HF Trial

  Tuesday, February 28, 2023
  11:14 AM – 11:22 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Late-Breaking Trials | Session Four

  Tuesday, February 28, 2023
  8:00 AM – 9:00 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• LATE-BREAKING TRIALS | SESSION FOUR

  Tuesday, February 28, 2023
  8:00 AM – 9:00 AM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• Panel Discussion: Defining Peri-Procedural MI in Clinical Trials

  Tuesday, February 28, 2023
  11:41 AM – 12:05 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)

• FDA LUNCEHON

  Tuesday, February 28, 2023
  12:05 PM – 1:30 PM ET

  Disclosure(s): Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo and V-wave: University Grants/Research Support (Ongoing); Abiomed, CorFlow, Apollo Therapeutics, Cardiomech, Gore, Amgen, Millennia Biopharma: Consultant (Terminated); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Medtronic, Pulnovo, Infraredx: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical: Consultant (Ongoing)